

contemplation of recommendations to the Secretary of HHS. The agenda for the meeting will include time for public comment. Meeting times and topics are subject to change.

Background on ICD-11: The International Classification of Diseases (ICD) is the global standard for health data, clinical documentation, and statistical aggregation. It provides a common language for recording, reporting, and monitoring diseases, allowing the world to compare and share data in a consistent and standard way—among hospitals, regions, and countries, and over periods of time. It facilitates the collection and storage of data for analysis and evidence-based decision-making by enabling systematic recording, reporting, analysis, interpretation, and comparison of mortality and morbidity data.

ICD-11 allows countries to count and identify their most pressing health issues using an up-to-date and clinically relevant classification system.^{2,3,4} Governments assign ICD-11 codes to health conditions and accidents so data can be used to design effective public health policies and measure their impacts, or so that clinicians can use the data for recording encounters with patients in a standard way.

Request for Information: This Notice also serves as a Request for Information (RFI) addressing the potential use of ICD-11 for morbidity coding in the U.S. We welcome responses from industry stakeholders, interested individuals and organizations, or any members of the public in advance of the August 3, 2023, expert roundtable meeting. The following questions are a guide to information the Workgroup would find particularly helpful, but respondents are invited to comment on any aspect of ICD-11 that they wish.

1. What would be the benefits of implementing ICD-11 for morbidity in your setting or organization?

2. What information or research will your organization need in order to inform assessments of cost, benefits, implementation approaches, communications, and outreach regarding the transition to ICD-11?

²ICD-11 was adopted at the World Health Assembly in May 2019 and Member States committed to start using it for mortality and morbidity reporting in 2022. Since 2019, early adopter countries, translators, and scientific groups have recommended further refinements to produce the version that is posted online today. World Health Organization (WHO) Press Release. (February 11, 2022): <https://paho.org/en/news/11-2-2022-whos-new-international-classification-diseases-icd-11-comes-effect>.

³WHO ICD-11 website: <https://icd.who.int/en>.

⁴WHO ICD-11 Fact Sheet: https://icd.who.int/en/docs/icd11factsheet_en.pdf.

Respondents may choose to refer to NCVHS' most recent recommendations to HHS for proposed research questions, many of which HHS has not yet addressed.⁵

3. What considerations affect the impact of ICD-11 on clinical documentation, payment processes including risk adjustment, public health, population health, or research?

4. What unique U.S. coding or terminology considerations are essential? For example, coding or terminology related to community health, social determinants of health, essential human needs, sexual orientation, gender identity and expression, obesity, external cause of injury, and information about mental, behavioral, or neurodevelopmental disorders including alignment with the Diagnostic And Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)?

5. How should HHS implement ICD-11 in the U.S. for morbidity coding?

6. The World Health Organization (WHO) recommends establishing a national center for ICD-11 implementation. What entity should be responsible for coordinating overall national implementation of ICD-11 for morbidity coding, and how should the implementation be managed?

7. ICD-11 uses an open process in which WHO encourages requests for updates and changes, thus eliminating the main drivers of national clinical modifications. What entity should be responsible for coordinating U.S. requests for updates or changes to ICD-11? How should this process be managed?

8. What resources, tools, or support will your organization need for implementation?

9. What kinds of technical resources, guidance, or tools should the U.S. Federal Government make available?

10. What workforce, workforce planning, or training will your organization need to support implementation?

11. What are your organization's requirements for ICD-11 mapping to other coding systems and terminologies, including value sets?

12. What other operational impacts of ICD-11 adoption and implementation should HHS consider?

The Committee will compile submitted responses in advance of the August 3, 2023, meeting and consider

⁵NCVHS Letter to HHS Secretary, "Updated Recommendations for Immediate Action on ICD-11 (September 10, 2021): <https://ncvhs.hhs.gov/wp-content/uploads/2021/09/NCVHS-ICD-11-recommendations-for-HHS-Sept-10-2021-Final-508.pdf>.

them together with input from subject matter experts during the meeting. To submit comments in response to the RFI, please send by June 30, 2023, to NCVHSmail@cdc.gov and include on the subject line: Response from [your organization or name] regarding ICD-11 RFI.

Sharon Arnold,

Associate Deputy Assistant Secretary, Office of Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 2023-12617 Filed 6-12-23; 8:45 am]

BILLING CODE 4150-05-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Cell and Molecular Biology.

Date: July 11–12, 2023.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Megan L. Goodall, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-8334, megan.goodall@nih.gov.

Name of Committee: Population Sciences and Epidemiology Integrated Review Group, Cardiovascular and Respiratory Diseases Study Section.

Date: July 11–12, 2023.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Mohammed F.A. Elfaramawi, Ph.D., MD, Scientific Review Officer, Center for Scientific Review,

National Institutes of Health, 6701 Rockledge Drive, Room 1007F, Bethesda, MD 20892, (301) 480-1142, elfaramawimf@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Cancer Diagnostics and Treatment (CDT).

Date: July 11-12, 2023.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Victor A. Panchenko, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 802B2, Bethesda, MD 20892, (301) 867-5309, victor.panchenko@nih.gov.

Name of Committee: Infectious Diseases and Immunology B Integrated Review Group, HIV Coinfections and HIV Associated Cancers Study Section.

Date: July 11-12, 2023.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn Washington, DC, Downtown, 1199 Vermont Ave. NW, Washington, DC 20005.

Contact Person: Joshua D. Powell, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive Bethesda, MD 20892, (301) 594-5370, josh.powell@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Topics in Health Services Research.

Date: July 11-12, 2023.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Mary Kate Baker, DRPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-5117, katie.baker2@nih.gov.

Name of Committee: Infectious Diseases and Immunology B Integrated Review Group, HIV Comorbidities and Clinical Studies Study Section.

Date: July 11-12, 2023.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Michael L. Bloom, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6187, MSC 7804, Bethesda, MD 20892, 301-451-0132, bloomm2@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Endocrine and Metabolic Systems.

Date: July 11, 2023.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Victoria Martinez Virador, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-4703, victoria.virador@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowship: HIV Clinical Care and Health Interventions.

Date: July 11, 2023.

Time: 10:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Abu Saleh Mohammad Abdullah, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1003-L, Bethesda, MD 20892, (301) 827-4043, abuabdullah.abdullah@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Fellowships: HIV/AIDS Biological Review Panel.

Date: July 11, 2023.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Anthony Chan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, (301) 496-9392, anthony.chan@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 7, 2023.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-12605 Filed 6-12-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Transmission of Vector-Borne and Zoonotic Diseases Study Section (TVZ), June 12, 2023, 10:00 a.m. to June 13, 2023, 08:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on May 15, 2023, 88 FR 30998 Doc 2023-10263.

This notice is being amended to change the meeting start time from 9:30 a.m. to 8:00 p.m. to 10:00 a.m. to 8:00 p.m. The meeting is closed to the public.

Dated: June 7, 2023.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-12606 Filed 6-12-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, NCI Program Project (P01) Review SEP-E, July 19, 2023, 12:00 a.m. to 5:00 p.m., National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W126, Rockville, Maryland 20850 which was published in the **Federal Register** on June 06, 2023, FR Doc 2023-11973, 88 FR 37079.

This notice is being amended to change the meeting start time from 12:00 a.m. to 12:00 p.m. The meeting end time, date, and location will stay the same. The meeting is closed to public.

Dated: June 7, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-12568 Filed 6-12-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-7070-N-31]

30-Day Notice of Proposed Information Collection: Title: Capital Needs Assessment (CNAs); OMB Control No.: 2502-0505

AGENCY: Office of Policy Development and Research, Chief Data Officer, HUD.

ACTION: Notice.

SUMMARY: HUD is seeking approval from the Office of Management and Budget (OMB) for the information collection described below. In accordance with the Paperwork Reduction Act, HUD is requesting comment from all interested parties on the proposed collection of information. The purpose of this notice is to allow for an additional 30 days of public comment.